Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065336 | 0.89 | KEAP1 (0.52) | ALDH1A1KEAP1SMN1; SMN2KDM4EKDM1A | |
| SCHEMBL28123666 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM1APOLB | |
| SCHEMBL235080 | 0.79 | KDM4E (0.65) | ALDH1A1KEAP1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL26462643 | 0.78 | HRH3 (0.46) | ALDH1A1POLBSIGMAR1KMT2AMAPT | |
| SCHEMBL7769654 | 0.77 | ATM (0.46) | ALDH1A1KEAP1SMN1; SMN2KDM4EKDM1A | |
| SCHEMBL10913328 | 0.76 | KDM4E (0.70) | ALDH1A1KEAP1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL11856358 | 0.76 | KDM4E (0.70) | ALDH1A1KEAP1SMN1; SMN2KDM4EPOLB | |
| SCHEMBL592806 | 0.74 | KDM1A (0.47) | ALDH1A1SMN1; SMN2KDM1APOLBSIGMAR1 | |
| SCHEMBL4758301 | 0.73 | TBXAS1 (0.50) | ALDH1A1KEAP1SMN1; SMN2KDM4E | |
| SCHEMBL1456338 | 0.73 | HTT (0.41) | ALDH1A1KEAP1SMN1; SMN2KDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109195965-A | The inhibitor that WDR5 protein-protein combines | 普罗佩纶治疗公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-1753668-A | 1, 5-diaryl pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20030199516-A1 | Methods of treating infection by drug resistant bacteria | GENESOFT, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199516-A1 | Methods of treating infection by drug resistant bacteria | POLI, POLN, PCNA | ALDH1A1 3899/4885KEAP1 1681/4885SMN1; SMN2 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.